Results 41 to 50 of about 32,827 (233)

Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance [PDF]

ecancermedicalscience, 2010
Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly ...
Seetharam, RN, Sood, A, Goel, S
openaire   +2 more sources

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M, Davey, Mary W., Davey, Mary W, Stordal, B, Britta Stordal, Mary Davey, Stordal, Britta   +6 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]

, 2013
Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
Yong J. Lee, Yong J. Lee (297943), Song, X, Lee, YJ, Seog-Young Kim, Song Xinxin, Xinxin Song, Kim Seog-Young, Yong J Lee, Xinxin Song (297942), Song, Xinxin, Lee Yong J., Kim, Seog-Young, Seog-Young Kim (297940), Kim, SY, Calogero, Raffaele A, Lee, Yong J.   +16 more
core   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11 [PDF]

Anticancer Research, 2018
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC. However, patients with
Beibei, Wang, Hisanobu, Ogata, Yuto, Takishima, Shohei, Miyamoto, Hiroyuki, Inoue, Masaki, Kuroda, Kazunari, Yamada, Yasuki, Hijikata, Mutsunori, Murahashi, Hiroyuki, Shimizu, Toshihiko, Okazaki, Yoichi, Nakanishi, Kenzaburo, Tani   +12 more
openaire   +2 more sources

A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer

Experimental Cell Research, 2020
There is growing evidence to support a role for the ceramide-metabolizing enzyme, glucosylceramide synthase (GCS), in resistance to a variety of chemotherapeutic agents. Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined.
James P, Madigan, Robert W, Robey, Joanna E, Poprawski, Huakang, Huang, Christopher J, Clarke, Michael M, Gottesman, Myles C, Cabot, Daniel W, Rosenberg   +7 more
openaire   +3 more sources

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer

Cell Death and Disease, 2022
Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients.
Xiaolong Tang, Yahang Liang, Guorui Sun, Qingsi He, Zhenyu Hou, Xingzhi Jiang, Peng Gao, Hui Qu   +7 more
doaj   +1 more source

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
Davey, Ross, Stordal, Britta
core   +1 more source

Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy

Clinical and Translational Medicine, 2022
AbstractBackgroundGastric carcinoma (GC) is one of the most deadly diseases due to tumour metastasis and resistance to therapy. Understanding the molecular mechanism of tumour progression and drug resistance will improve therapeutic efficacy and develop novel intervention strategies.MethodsDifferentially expressed long non‐coding RNAs (lncRNAs) in ...
Yu‐Feng Xiao, Bo‐Sheng Li, Jing‐Jing Liu, Su‐Min Wang, Jiao Liu, Huan Yang, Yi‐Yang Hu, Chun‐Li Gong, Ji‐Liang Li, Shi‐Ming Yang   +9 more
openaire   +3 more sources

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells

Oncotarget, 2017
Erythropoietin-producing hepatocellular receptor A2 (EphA2) is upregulated in gastric cancer tissues and cells, which is accompanied by epithelial-mesenchymal transition (EMT). The current study was designed to establish the oxaliplatin-resistant human gastric cancer cell line SGC-7901/L-OHP, to determine if EMT in these cells could be reversed, and to
Wen, Qiaocheng, Chen, Zihua, Chen, Zhikang, Chen, Jinxiang, Wang, Ran, Huang, Changhao, Yuan, Weijie   +6 more
openaire   +2 more sources